RxDoctor Payments DataLook up a doctor →

Erdal Diri, MD

Rheumatology · Minot, NDNPI 1245328681

Payments from drug & device makers

$1,346,480in general payments, 2019–2025

Across 558 payments — averaging $2413.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$512K
  • Novartis$416K
  • GSK$136K
  • Sun Pharmaceutical Industries Inc.$107K
  • Daiichi Sankyo Inc.$87K
  • Pfizer$49K
  • plus $39K from 6 others
$3,646in research payments, 2019–2025

Across 20 payments — averaging $182.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K
  • GSK$2K

What the payments were for

  • Food & beverage$21172%
  • Education$8028%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie201$512,396
Novartis7$416,016
GSK60$136,374
Sun Pharmaceutical Industries Inc.108$106,611
Daiichi Sankyo Inc.94$86,546
Pfizer52$49,239
Daiichi Sankyo Company LTD3$20,374
UCB GmbH2$11,944
Sanofi US Services Inc.21$6,534
Noven Pharmaceuticals, Inc.7$338
Johnson & Johnson1$80
Amgen(2 entities)2$28

How this compares

Too few rheumatology providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$43,153
Medicare patients
311
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab20$139,948
EnbrelEtanercept17$126,918
Cosentyx Sensoready (2 Pens)Secukinumab11$92,466
MethotrexateMethotrexate Sodium259$10,304
Pregabalin30$2,750
Prednisone257$2,457
Hydroxychloroquine Sulfate57$2,376
Sulfasalazine47$1,848
Gabapentin57$1,229
Leucovorin Calcium19$1,193
Celecoxib35$1,102
Diclofenac Sodium35$945
Febuxostat11$628
Duloxetine Hcl19$594
Meloxicam57$526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$28$126,91817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other rheumatology in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →